TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36525180

Group type: COMPARATOR
Intervention: TEC (docetaxel 75 mg/m2, epirubicin, and cyclophosphamide)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TECM (docetaxel, epirubicin, cyclophosphamide with metformin)
Number of subjects: 92

Group type: COMPARATOR
Intervention: TEC
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TECM
Number of subjects: 92

Group type: COMPARATOR
Intervention: TEC and TECM
Number of subjects: 92
Study: 36525272

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) from a lean donor
Number of subjects: 41

Group type: COMPARATOR
Intervention: Autologous placebo
Number of subjects: 41
Study: 36525287

Group type: EXPERIMENTAL
Intervention: App promoting weight gain prevention and healthy behaviors
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Access to a private Facebook group for peer support
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Questionnaires regarding health behaviors and breast cancer risk belief
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: App rating scales
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with approximately 20 participants
Number of subjects: 35
Study: 36525338

Group type: EXPERIMENTAL
Intervention: Esketamine plus a newly initiated oral antidepressant
Number of subjects: 764
Study: 36525340

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild cases of conjunctivitis (dupilumab and tralokinumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Severe cases of conjunctivitis (dupilumab and tralokinumab)
Number of subjects: 0
Study: 36525381

Group type: EXPERIMENTAL
Intervention: E-health (4-month subscription to the online Goalistics Chronic Pain Management Program)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 402
Study: 36525405

Group type: EXPERIMENTAL
Intervention: Extended contingency management (CM) intervention with escalating incentives contingent on abstinence
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group with fixed incentives for attending study visits
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Extended CM intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 36525493

Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody combined with neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody
Number of subjects: 0
Study: 36525540

Group type: EXPERIMENTAL
Intervention: CTO-PCI in ACS patients
Number of subjects: 558

Group type: COMPARATOR
Intervention: CTO-PCI in non-ACS patients
Number of subjects: 558
Study: 36525544

Group type: EXPERIMENTAL
Intervention: Life's Simple 7 (LS7) assessment of cardiovascular health (CVH)
Number of subjects: 735
Study: 36525606

Group type: EXPERIMENTAL
Intervention: Adding hydroxychloroquine and sulfasalazine for the first 12 weeks and then discontinuing TNFi for the following 48 weeks (Group A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Maintaining TNFi and MTX for 60 weeks (Group B)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Maintaining TNFi and MTX for the first 12 weeks and then discontinuing TNFi for the following 48 weeks (Group C)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Comparative analysis of Group A and Group B vs Group C
Number of subjects: 67
Study: 36525610

Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX
Number of subjects: 315

Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 315
Study: 36525620

Group type: EXPERIMENTAL
Intervention: TA (Treatment A)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: CO (Control)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Other ablation treatments
Number of subjects: 1152
Study: 36525627

Group type: EXPERIMENTAL
Intervention: Hybrid intervention combining Enhanced Milieu Teaching (EMT) and Joint Attention, Symbolic Play, Engagement, and Regulation (JASPER)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Behavior management control condition
Number of subjects: 120
Study: 36525653

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Bacteroides abundance
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Alpha diversity
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Beta diversity
Number of subjects: 455
Study: 36525797

Group type: EXPERIMENTAL
Intervention: MEDPass (50 ml of ONS four times per day with medication rounds)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional ONS administration (between meals)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MEDPass
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional ONS administration
Number of subjects: 204
Study: 36525851

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) + Fitbit
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) + Fitbit
Number of subjects: 340

Group type: COMPARATOR
Intervention: Fitbit only
Number of subjects: 340
Study: 36525985

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg (two capsules on day 1 followed by one capsule daily for 4 days)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo (matching capsules)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study: 36526251

Group type: EXPERIMENTAL
Intervention: Proactive, semistructured spiritual care intervention delivered by chaplains
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 192
Study: 36526263

Group type: EXPERIMENTAL
Intervention: Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOP-PFQ scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOP-PFQ
Number of subjects: 0
Study: 36526308

Group type: EXPERIMENTAL
Intervention: Video-based joint hypermobility assessment using smartphone camera
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical-grade goniometer measurements
Number of subjects: 0
Study: 36526425

Group type: EXPERIMENTAL
Intervention: Language therapy for 6 weeks
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Advanced brain age (n = 47)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Therapy outcome scores
Number of subjects: 93
Study: 36526481

Group type: EXPERIMENTAL
Intervention: Preoperative dexamethasone (1 mg/kg)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 157
Study: 36526480

Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stress balls
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 36526521

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) for 6 weeks prior to nephrectomy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Baseline levels of circulating biomarkers
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation analysis of circulating biomarkers
Number of subjects: 25
Study: 36526577

Group type: EXPERIMENTAL
Intervention: Positron emission tomographic (PET) and computed tomographic (CT) imaging using a novel glycoprotein IIb/IIIa receptor antagonist-based radiotracer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients without acute myocardial infarction)
Number of subjects: 0
Study: 36526640

Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36526739

Group type: EXPERIMENTAL
Intervention: Night Shift Fasting (NSF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Night Shift Eating (NSE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nighttime Sleep (NS)
Number of subjects: 10
Study: 36526794

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ketorolac (0.5 mg/kg)
Number of subjects: 212
Study: 36526796

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 36526815

Group type: EXPERIMENTAL
Intervention: Atovaquone treatment (Cohort 1, n=14)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment (Cohort 2, n=15)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall analysis of tumours
Number of subjects: 58
Study: 36526826

Group type: EXPERIMENTAL
Intervention: 3-month physical activity intervention (BEAT Cancer)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study: 36526846

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFR) covering all erupted teeth in the maxilla and first premolar to first premolar in the mandible.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bonded canine-to-canine retainers with VFR in the maxilla covering all erupted teeth.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both retention protocols (VFR and bonded retainers).
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFR).
Number of subjects: 104
Study: 36526898

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36526924

Group type: EXPERIMENTAL
Intervention: TBR Neurofeedback (NF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study: 36526937

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 109
Study: 36526947

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC 50/850 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC 50/1000 mg
Number of subjects: 82
Study: 36526961

Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 36527018

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention for panic-related anxiety
Number of subjects: 212

Group type: COMPARATOR
Intervention: Screening for panic attacks and panic disorder (Control)
Number of subjects: 212
Study: 36527025

Group type: EXPERIMENTAL
Intervention: 0.5 mg RT234
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1.0 mg RT234
Number of subjects: 86
Study: 36527073

Group type: EXPERIMENTAL
Intervention: AATD individuals with PI*ZZ genotype
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Individuals with impairment in FEV1(%) alone
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Individuals with impairment in KCO(%) alone
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: AATD individuals with advanced age, male sex, exacerbations, increased blood platelets and neutrophils, lower AAT serum levels
Number of subjects: 1044
Study: 36527074

Group type: EXPERIMENTAL
Intervention: Rehabilitation services (physical and cognitive domains)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Rehabilitation services at three or six months
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Higher number of transition of care (TOC) pathways
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Pre-morbid psychiatric problems
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Being male and having more than 13 years of education
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Sustaining major trauma
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Living in Southern and Eastern European regions
Number of subjects: 1379
Study: 36527120

Group type: EXPERIMENTAL
Intervention: Savings group (access to a savings account with lottery-based incentives, savings goals/strategies, and text message reminders)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (basic health education)
Number of subjects: 1500
Study: 36527143

Group type: EXPERIMENTAL
Intervention: Oral bolus of 100,000 IU with 10,000 IU/week of vitamin D
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 34
Study: 36527262

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (VMP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 144
Study: 36527367

Group type: EXPERIMENTAL
Intervention: Single injection of cross-linked hyaluronic acid (HANOX-M-XL)
Number of subjects: 51
Study: 36527386

Group type: EXPERIMENTAL
Intervention: BI 456906 (subcutaneous glucagon-like peptide-1 receptor/glucagon receptor dual agonist)
Number of subjects: 149
Study: 36527513

Group type: EXPERIMENTAL
Intervention: NK cells expanded ex vivo with K-562-41BBL-mbIL21 cell line
Number of subjects: 16
Study: 36527520

Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 63
Study: 36527570

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) assessed by a 10-min running test
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Muscular fitness assessed by sit-ups test
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Muscular fitness assessed by handgrip test
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Explosive strength in the lower body
Number of subjects: 1985
Study: 36527702

Group type: EXPERIMENTAL
Intervention: Extended CINV (≥3 days) in C1
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Short CINV (1-2 days) in C1
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: CINV duration monitoring and augmented antiemetic prophylaxis
Number of subjects: 402

Group type: COMPARATOR
Intervention: Complete response (CR) in C1
Number of subjects: 402

Group type: COMPARATOR
Intervention: Treatment failure (TF) in C1
Number of subjects: 402
Study: 36527859

Group type: EXPERIMENTAL
Intervention: FOREST intervention
Number of subjects: 168
Study: 36527955

Group type: EXPERIMENTAL
Intervention: Combined cognitive and exercise training (CT&E)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cognitive training alone (CT)
Number of subjects: 37
Study: 36528005

Group type: EXPERIMENTAL
Intervention: Higher stress
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Poorer sleep quality
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Poorer well-being
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: ACWR below 0.8 or above 1.3
Number of subjects: 471
Study: 36528035

Group type: EXPERIMENTAL
Intervention: KRd plus autologous stem-cell transplantation (ASCT)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: KRd plus ASCT
Number of subjects: 477
Study: 36528039

Group type: EXPERIMENTAL
Intervention: Oral favipiravir plus standard care (1800 mg twice daily for 1 day; 800 mg twice daily for 9 days)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Oral favipiravir plus standard care (in patients younger than 60 years)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard care alone (in patients younger than 60 years)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Oral favipiravir plus standard care
Number of subjects: 499
Study: 36528053

Group type: EXPERIMENTAL
Intervention: Telemedicine and medication delivery service (TMDS) called 'MotoMeds'
Number of subjects: 391
Study: 36528055

Group type: EXPERIMENTAL
Intervention: Exclusive human milk diet
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (mixed human and bovine diet)
Number of subjects: 107
Study: 36528108

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing in decidual tissues of missed-abortion group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single-cell RNA sequencing in decidual tissues of elective terminations
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Correlation analysis of senescent SCs and chromosomal abnormalities
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Assessment of HLA-KIR interaction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hypothesis on DIO2 marker of senescent SCs
Number of subjects: 34
Study: 36528113

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including advanced notification, mailed fecal immunochemical test (FIT) kits and reminders
Number of subjects: 9699

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9699
Study: 36528115

Group type: EXPERIMENTAL
Intervention: Fat mass index (FMI)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Lean body mass index (LBMI)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Discordant FMI above the median with BMI below
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: BMI above the median with FMI below
Number of subjects: 356
Study: 36528340

Group type: EXPERIMENTAL
Intervention: 165-SNP polygenic risk score (PRS) developed with PLINK
Number of subjects: 785

Group type: COMPARATOR
Intervention: Previously-published PRS
Number of subjects: 785
Study: 36528376

Group type: EXPERIMENTAL
Intervention: Emraclidine 30 mg once daily
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Emraclidine 20 mg twice daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Emraclidine (combined groups)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Emraclidine groups
Number of subjects: 130
Study: 36528443

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP∼T vaccine (Hexyon™, Sanofi) administered at 8, 12, 16 weeks and booster at 13 months (preterm) or 15 months (term)
Number of subjects: 332
Study: 36528522

Group type: EXPERIMENTAL
Intervention: BI 1810631 (15 mg BID, escalating doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1810631 (escalating doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1810631
Number of subjects: 0
Study: 36528547

Group type: EXPERIMENTAL
Intervention: Personal protective aids
Number of subjects: 0
Study: 36528590

Group type: EXPERIMENTAL
Intervention: Deployment of male Wolbachia-infected Ae. aegypti mosquitoes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Incompatible insect technique coupled with sterile insect technique (IIT-SIT)
Number of subjects: 15
Study: 36528609

Group type: EXPERIMENTAL
Intervention: Smartphone app DiaCert promoting physical activity for 3 months in addition to routine care
Number of subjects: 181

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 181
Study: 36528670

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 34000

Group type: COMPARATOR
Intervention: Comparator GLDs
Number of subjects: 34000
Study: 36528677

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load testing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Centralized viral load testing
Number of subjects: 68
Study: 36528682

Group type: EXPERIMENTAL
Intervention: Incident hypertension
Number of subjects: 152

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Machine learning clustering
Number of subjects: 152
Study: 36528761

Group type: EXPERIMENTAL
Intervention: Bilateral anterior 1-s RMS on the neck
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different coil shapes and stimulation locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventilation over 10 min
Number of subjects: 0
Study: 36528793

Group type: EXPERIMENTAL
Intervention: AZD8601 (3 mg total, 30 epicardial injections)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo in citrate-buffered saline
Number of subjects: 30
Study: 36528982

Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study: 36528984

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 36528997

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training program (one 60 min group exercise session per week for 8 weeks + online home exercise program for 8 weeks)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training program
Number of subjects: 167
Study: 36529030

Group type: EXPERIMENTAL
Intervention: Interferon gamma-induced protein-10 (IP-10) concentrations of 2000 pg/ml or higher
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Anakinra treatment
Number of subjects: 534

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) and TNF-related apoptosis-inducing ligand (TRAIL)
Number of subjects: 534
Study: 36529052

Group type: EXPERIMENTAL
Intervention: CoronaVac (first dose on D0, second dose on D28, booster dose on D210)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CoronaVac
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Booster dose of CoronaVac (D240)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Prednisone treatment
Number of subjects: 53
Study: 36529089

Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC) 300 mcg on days 1-3 and 60 mcg on days 4-27
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC)
Number of subjects: 171
Study: 36529106

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease and insomnia (ADI)
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Elderly individuals with insomnia (EI)
Number of subjects: 1076